Advertisement
U.S. markets closed

T2 Biosystems, Inc. (TTOO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.55+0.03 (+0.54%)
At close: 04:00PM EST
5.35 -0.20 (-3.59%)
After hours: 06:33PM EST

T2 Biosystems, Inc.

101 Hartwell Avenue
Lexington, MA 02421
United States
781 761 4646
https://www.t2biosystems.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees158

Key Executives

NameTitlePayExercisedYear Born
Mr. John J. Sperzel III, B.Sc.President, CEO & Chairman865.5kN/A1963
Mr. John M. Sprague CPAChief Financial Officer482.33kN/A1958
Mr. Michael Terrence Gibbs Esq.Senior VP, General Counsel & Company Secretary487.33kN/A1971
Ms. Kelley J. MorganChief People OfficerN/AN/A1976
Mr. Brett A. GiffinChief Commercial OfficerN/AN/A1959
Dr. Roger Smith Ph.D.Senior Vice President of Science Research & DevelopmentN/AN/A1965
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Corporate Governance

T2 Biosystems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.